Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 12/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15633163 | 0.78 | PARP1 (0.51) | PARP1TSHRPOLBNPC1HSP90AA1 | |
| SCHEMBL10222520 | 0.78 | ATM (0.52) | PARP1TSHRPOLBPRMT5ATM | |
| SCHEMBL17515573 | 0.76 | GRM4 (0.50) | GRM4 | |
| SCHEMBL25072358 | 0.75 | PARP1 (0.51) | PARP1TSHRPOLBNPC1HSP90AA1 | |
| SCHEMBL1252531 | 0.75 | PARP1 (0.51) | PARP1TSHRHSP90AA1L3MBTL1ATM | |
| SCHEMBL30169667 | 0.74 | PARP1 (0.62) | PARP1TSHRPOLBPRMT5WDR77 | |
| SCHEMBL24835102 | 0.74 | PARP1 (0.62) | PARP1TSHRPOLBPRMT5WDR77 | |
| SCHEMBL18237397 | 0.74 | PARP1 (0.48) | PARP1TSHRPOLBNPC1HSP90AA1 | |
| SCHEMBL12689594 | 0.73 | GRM4 (0.39) | PARP1NPC1HSP90AA1L3MBTL1GRM4 | |
| SCHEMBL19153217 | 0.71 | PARP1 (0.49) | PARP1TSHRNPC1HSP90AA1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210179621-A1 | Toll-Like Receptor 8 (TLR8) Specific Antagonists and Methods of Making and Uses Thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2021-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179621-A1 | Toll-Like Receptor 8 (TLR8) Specific Antagonists and Methods of Making and Uses Thereof | TLR8, TLR3, TLR9 | PARP1 1146/4885TSHR 544/4885POLB 2448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.